Paion

EQS-News: PAION AG announces change in Management Board

Retrieved on: 
Wednesday, November 30, 2022
Marketing, Diple, Pleasure, Remimazolam, University, Financial Oversight and Management Board for Puerto Rico, Frankfurt Stock Exchange, AGR, Aktiengesellschaft, RTÉ Executive Board, Patient, Angiotensin, Critical care, Anesthesia, ISIN, Multiplicity of infection, Paion, Health, Abbott, Infection, Hypotension, Supervisory board, Septic, University Hospital Bonn, Distributive shock, EU, Management, Pharmaceutical industry, Pfizer

Dr. James Phillips leaves PAION AG as of 30 November 2022 by mutual agreement with the company.

Key Points: 
  • Dr. James Phillips leaves PAION AG as of 30 November 2022 by mutual agreement with the company.
  • Furthermore, Mr Gregor Siebert, currently a member of the Supervisory Board, will be appointed by the Supervisory Board of PAION AG as a member of the Management Board and Chairman of the Management Board pursuant to section 105 (2) of the German Stock Corporation Act (AktG) for a period from 1 December 2022 until 30 November 2023 to succeed Dr. Phillips.
  • At the same time, we wish Mr. Siebert every success in his role as CEO and Chairman of the Management Board.
  • Gregor Siebert has been a member of the Supervisory Board of PAION AG since May 2022.

EQS-News: PAION AG enters partnership with Viatris and expands sales activities in Europe

Retrieved on: 
Sunday, November 27, 2022
Growth, Frankfurt Stock Exchange, EMA, Partnership, Physician, Patient, Angiotensin, Critical care, ISIN, Paion, Multiplicity of infection, Hypotension, Septic, Distributive shock, Medis, Security (finance), Pharmaceutical industry, Viatris, Eravacycline, Anesthesia, Remimazolam, EU

Under the terms of the collaboration agreement, on the one hand, PAION will receive a upfront payment.

Key Points: 
  • Under the terms of the collaboration agreement, on the one hand, PAION will receive a upfront payment.
  • In addition, Viatris will purchase supply of the products from PAION and also share with them the profits from product sales.
  • Commenting on the sales activities, Dr. Jim Phillips, CEO of PAION AG, said: "We are very pleased to have entered into a long-term partnership with leading global healthcare company Viatris to provide access to medicines for patients in Europe.
  • This is an important milestone for PAION to drive forward its sales activities in Europe in a targeted manner.

DGAP-News: ​​​​​​​PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2021

Retrieved on: 
Wednesday, May 12, 2021
Paion

Jim Phillips, CEO of PAION AG, commented: "The first quarter of 2021 brought important progress in our transformation into a specialty pharma company.

Key Points: 
  • Jim Phillips, CEO of PAION AG, commented: "The first quarter of 2021 brought important progress in our transformation into a specialty pharma company.
  • We are now building our commercial organization and preparing launches for all three products in the second half of 2021, addressing important unmet medical needs.
  • PAION and Mundipharma have agreed on an amendment of the royalty calculation in the first quarter of 2021.
  • In the first quarter of 2021, the risks and opportunities have not changed significantly.\nPAION confirms its outlook for the current fiscal year given in March 2021 with the publication of the 2020 consolidated financial statements and group management report.

DGAP-News: PAION AG ANNOUNCES SUCCESSFUL COMPLETION OF CAPITAL INCREASE WITH SUBSCRIPTION RIGHTS

Retrieved on: 
Wednesday, April 7, 2021
Paion, Paeon

Aachen (Germany), 07 April 2021 - The specialty pharmaceutical company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard) today announces that the Company has successfully completed its rights offering.

Key Points: 
  • Aachen (Germany), 07 April 2021 - The specialty pharmaceutical company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard) today announces that the Company has successfully completed its rights offering.
  • PAION will use the net proceeds from the capital increase to prepare commercial launches for its product portfolio in selected European countries and for general corporate purposes.
  • PAION AG's CEO Dr. Jim Phillips commented: "We appreciate the great interest in the capital increase.
  • PAION AG is a publicly listed specialty pharmaceutical company with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services.

DGAP-News: PAION ANNOUNCES PRODUCT LAUNCH OF BYFAVO (REMIMAZOLAM) IN SOUTH KOREA BY HANA PHARM

Retrieved on: 
Wednesday, April 7, 2021
Feminine given names, Given names, Pyridines, Remimazolam, Paion, Paeon, Hana, remimazolam, PAION

Aachen (Germany), 07 April 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that Hana Pharm, remimazolam licensee for South Korea, informed PAION about the launch of ByfavoTM (remimazolam) for the use in general anesthesia in South Korea.

Key Points: 
  • Aachen (Germany), 07 April 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that Hana Pharm, remimazolam licensee for South Korea, informed PAION about the launch of ByfavoTM (remimazolam) for the use in general anesthesia in South Korea.
  • Remimazolam was approved in South Korea for general anesthesia in January 2021 and will be marketed under the brand name ByfavoTM.
  • Dr. Jim Phillips, Chief Executive Officer of PAION AG, stated: "The launch in South Korea is great news and a testament to the strong commitment of our partner Hana Pharm.
  • PAION is eligible to royalties of 10% of net sales in South Korea.

DGAP-News: ​​​​​​​PAION AG REPORTS ON SUCCESSFUL FISCAL YEAR 2020

Retrieved on: 
Tuesday, March 30, 2021
Chemical compounds, Organic compounds, Benzodiazepines, Pyridines, Remimazolam, Paion, Sedation, Paeon

Outstanding milestones were the first approvals of remimazolam in key pharma markets and the first successful launches by our partners.

Key Points: 
  • Outstanding milestones were the first approvals of remimazolam in key pharma markets and the first successful launches by our partners.
  • The associated milestone payments have led to a positive full-year result in 2020," commented Dr. Jim Phillips, CEO of PAION AG.
  • In Europe, remimazolam (trade name Byfavo(R)) is approved in procedural sedation and in addition PAION is seeking approval for general anesthesia.
  • In January 2020, PAION and Hana Pharm extended their license agreement for remimazolam to include Southeast Asia (Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam).

DGAP-News: PAION GRANTS EXCLUSIVE LICENSE TO TTY BIOPHARM FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN TAIWAN

Retrieved on: 
Friday, March 5, 2021
Chemical compounds, Organic compounds, Benzodiazepines, Pyridines, Remimazolam, Tty, Paion, Tty, Paeon, remimazolam, TTY Biopharm, PAION

Aachen (Germany), 05 March 2021 - PAION AG, a specialty pharma company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8), and TTY Biopharm Company Limited ("TTY") today announce that they have entered into a license agreement for remimazolam with PAION granting TTY an exclusive license for the development and commercialization of PAION's lead drug candidate, remimazolam, in Taiwan.

Key Points: 
  • Aachen (Germany), 05 March 2021 - PAION AG, a specialty pharma company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8), and TTY Biopharm Company Limited ("TTY") today announce that they have entered into a license agreement for remimazolam with PAION granting TTY an exclusive license for the development and commercialization of PAION's lead drug candidate, remimazolam, in Taiwan.
  • Under the terms of the agreement, TTY has the right and obligation to further develop remimazolam in all indications in Taiwan with PAION's support.
  • Dr. Jim Phillips, CEO of PAION AG, commented: "We are excited to have TTY as our partner for remimazolam in Taiwan.
  • Remimazolam, developed by PAION, has been approved in many countries and is a promising medicine for physicians and patients.

DGAP-News: PAION ANNOUNCES SUCCESSFUL PRODUCT LAUNCH OF ANEREM (REMIMAZOLAM) IN JAPAN BY MUNDIPHARMA

Retrieved on: 
Friday, August 7, 2020
Chemical compounds, Organic compounds, Benzodiazepines, Pyridines, Remimazolam, Anesthesia, Royalty payment, Paion, remimazolam, PAION

Aachen (Germany), 07 August 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that Mundipharma, remimazolam licensee for Japan, informed PAION about the successful launch with first commercial product sales of Anerem(R) (remimazolam) for the use in general anesthesia in Japan.

Key Points: 
  • Aachen (Germany), 07 August 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that Mundipharma, remimazolam licensee for Japan, informed PAION about the successful launch with first commercial product sales of Anerem(R) (remimazolam) for the use in general anesthesia in Japan.
  • PAION is eligible to royalties between 16-18% in Japan.
  • In Japan, licensee Mundipharma received market approval in general anesthesia in January 2020.
  • The topline data of a Phase III trial in general anesthesia are expected in the second half of 2020.

DGAP-News: U.S. LICENSE AGREEMENT FOR BYFAVOTM (REMIMAZOLAM) BETWEEN PAION AND COSMO ASSIGNED FROM COSMO TO ACACIA

Retrieved on: 
Wednesday, July 15, 2020
Chemical compounds, Organic compounds, Paion, Remimazolam, Paeon, remimazolam, PAION

Aachen (Germany), 15 July 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that PAION, U.S. remimazolam licensee Cosmo Pharmaceuticals NV ("Cosmo") and Acacia Pharma ("Acacia") have agreed to assign the BYFAVOTM (remimazolam) license agreement signed in 2016 between Cosmo and PAION to Acacia.

Key Points: 
  • Aachen (Germany), 15 July 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that PAION, U.S. remimazolam licensee Cosmo Pharmaceuticals NV ("Cosmo") and Acacia Pharma ("Acacia") have agreed to assign the BYFAVOTM (remimazolam) license agreement signed in 2016 between Cosmo and PAION to Acacia.
  • The terms of the license agreement remain unchanged but will now be between PAION and Acacia, with Cosmo no longer being a party to the agreement.
  • Alessandro Della Ch, CEO of Cosmo, said: "This assignment is important in order to let Acacia entertain a direct relationship with PAION.
  • We look forward to continue to contribute to the success of BYFAVOTM as shareholders of both Acacia and PAION."

DGAP-News: PAION REPORTS FULL CONVERSION OF CONVERTIBLE NOTES

Retrieved on: 
Wednesday, July 8, 2020
Chemical compounds, Organic compounds, Benzodiazepines, Pyridines, Remimazolam, Yorkville, Toronto, Yorkville, Convertible bond, Paion, Sedation, Paeon, Convertible security, remimazolam, PAION

Aachen (Germany), 08 July 2020 - The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that the EUR 5 million convertible notes issued to Yorkville Advisors Global, LP (Yorkville) in September 2019 have been converted into a total of 2,363,350 PAION shares.

Key Points: 
  • Aachen (Germany), 08 July 2020 - The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that the EUR 5 million convertible notes issued to Yorkville Advisors Global, LP (Yorkville) in September 2019 have been converted into a total of 2,363,350 PAION shares.
  • The convertible notes have thus been converted completely and a further use of the financing agreement with Yorkville is not planned.
  • Abdelghani Omari, CFO of PAION AG, commented: "We would like to thank Yorkville for their support over the last year.
  • In Europe, PAION is seeking approval of remimazolam for general anesthesia and for procedural sedation.